We subsequently demonstrated for the first time that riboswitch-mediated over-expression of an anti-VEGF agent is able to prevent CNV formation in an inducible manner following a single intravitreal injection of rAAV, potentially opening the door to a life-long, minimally invasive, but adaptable gene therapy treatment for neovascular/wet AMD. The gene discussed is VEGFA; the disease is age-related macular degeneration.